# Call for Proposals Transparency International UK Health Action Fund

# Technology-driven Solutions for Tackling Corruption in Sub-Saharan Africa

### Purpose

The Pharmaceuticals & Healthcare Programme (PHP) is one of the five Transparency International (TI) Global Network Thematic Initiatives (GNTI). The purpose of Transparency International’s Pharmaceuticals & Healthcare Programme **is to achieve genuine change in the pharmaceutical & healthcare sector through reducing corruption and promoting transparency, integrity and accountability**. We will apply TI’s strengths and expertise to contribute to the Programme’s overall goal **of improving global health and healthcare outcomes for the benefit of all people of all ages.**

A winning strength of the Programme is the size, scope and expertise of the TI Movement. Many Chapters already have a distinguished track record of work in this area. The structure and initial activities of the Programme have been designed to capitalize on the qualities of the TI Movement. The Health Action Fund will allow disbursal of grants to TI national chapters from anywhere in the network to fund activities, in whole or in part, that are contributing towards the Programme long term goals as outlined in the PHP Strategic Framework (Annex 1).

In its second instalment, the Health Action Fund, in cooperation with the Indigo Trust, is seeking out opportunities to support innovative, technology-driven solutions to overcome barriers to accessing healthcare, and ensuring the accessibility of quality and affordable medicinal products. **This Call for Proposals is directed specifically at TI Chapters in Sub-Saharan Africa.**

Applicants are encouraged to put forward projects that seek to support increased transparency relating e.g. to Research & Development, Manufacturing, Marketing, and Service Delivery.

### Eligibility

Applications under this Call for Proposals can be submitted by any TI National Chapter or Chapter in Formation in Sub-Saharan Africa. Chapters can submit one sole proposal and/or multiple joint proposals involving two or more Chapters. There are no restrictions on the location, size or types of activities within proposed projects but projects should begin within three months of the grant being awarded and have a total duration of six months.

Proposed projects must relate to one of the long term results or intermediary results within the PHP Strategic Framework (Annex 1). Applications must clearly demonstrate the outcome that the proposed project is seeking to achieve, and how it will contribute to one or more of the PHP long term or intermediary results.

In particular, applications will be assessed against the following criteria:

* **Relevance** of the proposed project in relation to the subject of this Call for Proposals
* **Quality of the proposal** document(s), clarity of the proposed outcome and feasibility of the project being implemented within a three-month timeframe
* **Potential for concrete and immediate application** of the skills/ knowledge acquired through the project, and for sustainability of the capacity development outcome
* **Potential for scalability and replication** of the capacity development experience across the TI Movement
* **Strong commitment** to the proposed initiative of the Board and senior staff of the applicant Chapters
* **Project budgets** make the best use of the total funding to be disbursed.

Decisions on allocation of funding will be taken by the PHP International Programme Committee.

### Available Funding

The funding for the Health Action Fund comes from the Programme core finances.

**Proposed projects should have a total budget of between GBP 5,000 and GBP 15,000.**

Grants will be disbursed to make best use of the total available funds, therefore successful applicants may be asked to revise budgets.

Funds awarded may be used to support proposed projects independently or as part of a co-funded initiative.

### Timeline

|  |  |
| --- | --- |
| **Activity** | **Date / Period** |
| Deadline for applications | 23:59 GMT (London time zone)  19 February 2017 |
| Deadline for grant allocation | 22 March 2017 |
| Signature of grant agreements | 7 April 2017 |
| Implementation period | April 2017 – October 2017 |
| Final reporting deadline | November 2017 |

### Reporting Requirements

At the time of project commencement, Chapters receiving a grant will be asked to complete a project risk assessment. Following project completion, Chapters must complete a financial and narrative report, as well as complete a TI Impact Matrix as applicable. Templates will be made available by the TI-UK contact person (see below), and submission deadlines are indicated above.

### Application Documents

All necessary grant application documents can be found in Annex 2 of this Call for Proposals. Proposals must be submitted in English language.

In order for applications to be considered, Chapters must submit the completed grant request form by the application deadline to [sarah.harris@transparency.org.uk](mailto:sarah.harris@transparency.org.uk) (Sarah Harris, PHP Senior Programme Officer, TI-UK). Late applications will not be considered.

If a proposed project is to be implemented by more than one Chapter (joint proposal) only one application form should be filled in. A lead Chapter should be identified to represent the group and submit the proposal on behalf of all participants.

Kindly note that all applications must follow the above procedure in order to be considered. If you have any concerns regarding the outlined procedure, please approach the contact person for this call (see below).

### Contact

For more information, please contact Sarah Harris at [sarah.harris@transparency.org.uk](mailto:sarah.harris@transparency.org.uk), +44 (0)20 3096 7684.

Those applying are welcome to ask questions regarding the application process but the programme cannot provide any information that will give an unfair advantage to any applicant. All questions asked and answers given will be made available via the webpage advertising this Call for Proposals.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **GOAL**  Improving global health and healthcare outcomes for the benefit of all people of all ages. | | | | | | |
| **PURPOSE**  To achieve genuine change in the pharmaceutical & healthcare sector through reducing corruption and promoting transparency, integrity and accountability. | | | | | | |
| **FIELDS OF ACTIVITY** | | | | | | |
| Global Policy & Structural Change | | Establishing Global Standards | | | Supporting National Level Projects | |
| **Long term result 1**  Adoption and enforcement of transparent and accountable health-related **procurement and distribution** policies and practices at the sub-national, national and global level | **Long term result 2**  Multi-national, national and state-owned pharmaceutical companies and their affiliates and associates adopt and enforce adequate **marketing practices** to prevent undue influence over healthcare professionals, public health institutions, regulators and legislators; and the demand-side is appropriately regulated with effective compliance | | **Long term result 3**  Significant progress towards eliminating corruption from healthcare and pharmaceutical **manufacturing** whether by multi-national, national or state-owned companies or by moderating the enabling environment for counterfeit manufacturing | **Long term result 4**  Comprehensive and systemic change has been made to improve the quality of **service delivery** at the patient level. | | **Long term result 5**  **Research & Development** are undertaken in a manner that is transparent, avoids conflicts of interest, and places the best healthcare outcomes at the heart of decision-making |
| **Intermediary result 1.1**  National health system procurement anti-corruption best practices are identified and made accessible | **Intermediary result 2.1**  Promotion and monitoring of anti-corruption international, regional and national standards and sanctions within company operations. | | **Intermediary result 3.1**  Multi-national, national and state-owned pharma companies and manufacturers of drugs and medical commodities adopt and enforce international standards for reducing corruption in manufacturing | **Intermediary result 4.1**  Patients are made aware of their rights within healthcare and are able to effectively exercise said rights. | | **Intermediary result 5.1**  Clinical research organisations, private sector pharmaceutical companies and private investors, academic institutions, and national and regional health regulatory authorities to increase transparency and ethical conduct in clinical trials to ensure greater objectivity, including disclosure of sources of funding and publishing research and clinical trials (incl. failed/negative tests) in open data |
| **Intermediary result 1.2**  National governments advocate the adoption and enforcement of transparent and accountable government procurement policies | **Intermediary result 2.2**  Adequate disclosure of information relating to interactions between companies and healthcare professionals and organisations | | **Intermediary result 3.2**  Government authorities ensure corruption-free issuance of manufacturing licenses and effective quality control | **Intermediary result 4.2**  Health practitioners are less susceptible to corruption at the point of service delivery at the patient level. | |  |
| **Intermediary result 1.3**  Relevant oversight agencies have the independence, knowledge and capacity to enforce anti-corruption policies and regulations that address the corruption risks in the sector | **Intermediary result 2.3**  Relevant actors including health regulatory authorities and industry bodies codify and regulate the scope and relationship between suppliers and healthcare professionals and organisations | | **Intermediary result 3.3**  Great knowledge and understanding and control the enabling environment of counterfeit pharmaceutical manufacturers, including the distribution chain |  | |  |
| **Intermediary result 1.4**  National government, suppliers and multi-lateral organisations increase transparency of medicines pricing to adequate levels |  | |  |  | |  |
| **Intermediary result 1.5**  Reduce corruption in distribution of essential medicines and in preventing patients from accessing medicines and treatment |  | |  |  | |  |

# Grant Application Form

This form should be filled in electronically. Proposal submissions **should not exceed 4-5 pages**.

|  |  |
| --- | --- |
| Applicant Information | |
| Name of organisation |  |
| Country |  |
| Implementing officer |  |
| Phone |  |
| Email |  |

|  |  |
| --- | --- |
| Funding Requirement | |
| Grant amount required |  |
| Currency |  |
| Amount of co-funding[[1]](#footnote-1) |  |
| Expected start date |  |
| Expected end date |  |

|  |
| --- |
| Project Title |
|  |

|  |
| --- |
| Project Summary (max. 50 words) |
|  |

|  |
| --- |
| Expected Impact: what is the expected impact on your project beneficiaries? What change(s) will the project bring about? |
|  |

|  |
| --- |
| Expected Results: what are the measurable results that the project will achieve[[2]](#footnote-2)? |
|  |

|  |
| --- |
| Strategy/Approach: how do you plan to achieve the impact and results? |
|  |

|  |
| --- |
| Strategic relevance of the project: how does the project fit with your Chapter’s strategic plan? (maximum 150 words) |
|  |

|  |
| --- |
| Which PHP long term or intermediary result does the project contribute towards? |
|  |

|  |
| --- |
| How does the project fit within the selection criteria described in the Call for Proposals? |
|  |

|  |
| --- |
| How will the impact of the project be sustained after the funding ends? Will the activities continue? |
|  |

|  |  |  |
| --- | --- | --- |
| Please list below all people (staff, consultants, resource persons) who will be involved in the implementation or oversight of the project, and what their role will be. | | |
| Name | Position | Role |
|  |  |  |
|  |  |  |
|  |  |  |

|  |  |
| --- | --- |
| Budget Summary | |
| Activity / Item | Cost |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |

|  |
| --- |
| [Insert any additional information required from the applicant, if needed. If not, delete this section] |
|  |

|  |
| --- |
| Signature of Chapter Representative |
| Signature |
| Name |
| Position |
| Date |

1. Co-funding refers to any funding that your Chapter (through your own funds or other grants) commits to contribute to the project, in addition to the grant you are applying for. For instance, the grant may only cover a certain percentage of the budget needed to implement the project. In this case, please indicate how much co-funding you will commit to the project. [↑](#footnote-ref-1)
2. Please ensure that your proposal reflects the expected outcomes and scope of activities described in the Call for Proposals. [↑](#footnote-ref-2)